Company intelligence / Profile preview

Endovascular Engineering

Menlo Park, California, United Statesendovascularengineering.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Endovascular Engineering has completed a 25-patient feasibility phase of the ENGULF clinical trial for its Hēlo PE Thrombectomy System, demonstrating safety and feasibility in intermediate-risk pulmonary embolism patients. The pivotal phase is ongoing to support FDA 510(k) clearance. Early results show successful outcomes with the device for acute submassive PE; all pivotal trial patients are treated with an updated version of the system designed to optimize clot engagement and minimize blood loss.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Hēlo PE Thrombectomy System

Phase 3

Indications: Pulmonary embolism, Venous thromboembolism

Partnerships

Cordis (strategic partnership)

Beyond the preview

Go deeper on Endovascular Engineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endovascular Engineering.

Explore the full profile